Torrent Pharmaceuticals Limited has informed the Exchange that Board of Directors at its meeting held on February 13, 2026, declared Interim Dividend of 29 per equity share.
TORNTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.8 pts more than Nifty 100 and 5.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Torrent Pharmaceuticals reported Q3 FY26 (Dec 31, 2025) consolidated revenue of ₹3,303 crores, up 18% year-on-year, with operating EBITDA at ₹1,088 crores (up 19% YoY) and net profit after tax at ₹635 crores, up 26% YoY. For the nine-month period, revenue grew 14% to ₹9,783 crores and PAT rose 26% to ₹1,774 crores. Geography-wise, India revenues grew 14% to ₹1,798 crores, Brazil 27% to ₹371 crores, US 19% to ₹321 crores, and Germany 8% to ₹304 crores. The Board declared an interim dividend of ₹29 per share (580% on face value of ₹5), expected to be paid on or around March 6, 2026. The company also completed the acquisition of a 48.8% controlling stake in J.B. Chemicals & Pharmaceuticals, making Torrent the 5th largest pharma company in India by market share. Debt-equity ratio improved to 0.14 (standalone) from 0.24 in the previous quarter after repaying listed NCDs of ₹143 crores.
Strong Q3 results with double-digit revenue and profit growth, coupled with a generous interim dividend, signal robust cash generation and are likely to support positive investor sentiment. The completion of the JB Pharma acquisition significantly expands Torrent's domestic market position, though integration costs of ₹23 crores (exceptional items) and pending merger approvals remain near-term watchpoints.